GCP
DSGN icon

GSA Capital Partners’s Design Therapeutics DSGN Stock Holding History

GSA Capital Partners’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-59,975
Closed -$202K – 1751
2025
Q2 		$202K Sell
59,975
-12,174
-17% -$45.6K 0.01% 1503
2025
Q1 		$278K Sell
72,149
-46,179
-39% -$220K 0.03% 1205
2024
Q4 		$730K Sell
118,328
-55,416
-32% -$321K 0.05% 619
2024
Q3 		$935K Sell
173,744
-36,209
-17% -$170K 0.07% 511
2024
Q2 		$703K Sell
209,953
-6,394
-3% -$24.9K 0.05% 753
2024
Q1 		$872K Buy
216,347
+144,055
+199% +$385K 0.07% 533
2023
Q4 		$192K Buy
72,292
+28,711
+66% +$65.8K 0.02% 1331
2023
Q3 		$103K Sell
43,581
-194,619
-82% -$908K 0.01% 1383
2023
Q2 		$1.5M Buy
238,200
+140,300
+143% +$859K 0.15% 140
2023
Q1 		$565K Buy
97,900
+84,281
+619% +$630K 0.06% 630
2022
Q4 		$140K Buy
+13,619
New +$185K 0.02% 1259

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

GSA Capital Partners's DSGN Position: Q3 2025 in Review

GSA Capital Partners sold out of Design Therapeutics (DSGN) in Q3 2025, closing a stake of 59,975 shares — an estimated $202K sold.

GSA Capital Partners first reported a position in DSGN in Q4 2022 and held it in 11 quarters. The position peaked at $1.5M in Q2 2023. 95 funds tracked by Wall St. Rank hold DSGN as of Q3 2025.

  • GSA Capital Partners reported no remaining Design Therapeutics position as of Q3 2025 after selling out during the quarter.
  • GSA Capital Partners sold 59,975 Design Therapeutics shares in Q3 2025, an estimated $202K.
  • GSA Capital Partners first reported a position in Design Therapeutics in Q4 2022 and held it in 11 quarters.
  • GSA Capital Partners's Design Therapeutics position peaked at $1.5M in Q2 2023.
  • 95 funds tracked by Wall St. Rank held Design Therapeutics as of Q3 2025.

Based on GSA Capital Partners's 13F filing for Q3 2025, filed 7 Nov 2025.